Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MannKind Corporation
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Lilly’s diabetes and oncology franchises epitomize the effects of the pandemic on pharmaceutical sales. For much smaller companies, these effects were magnified.
- Medical Devices
- Drug Delivery
- Other Names / Subsidiaries
- QrumPharma, Inc.